Description: SciSparc Ltd., a specialty clinical-stage pharmaceutical company, develops drugs based on cannabinoid molecules. Its drug development programs include SCI-110 for the treatment of Tourette syndrome, obstructive sleep apnea, and Alzheimer's disease and agitation; SCI-160 for the treatment of pain; and SCI-210 for the treatment of autism spectrum disorder and epilepsy. SciSparc Ltd. has an agreement with Procaps to develop and commercially manufacture SCI-110, as well as CannAmide, a palmitoylethanolamide compound in softgel capsule form. It also has an agreement with the Sheba Fund for Health Services and Research to perform a pre-clinical study for the evaluation of SCI-210 drug development program for the treatment of status epilepticus; and The Israeli Medical Center for Alzheimer's to conduct a phase IIa clinical trial to evaluate the safety, tolerability, and efficacy of SCI-110 in patients with Alzheimer's disease and agitation. The company was formerly known as Therapix Biosciences Ltd. and changed its name to SciSparc Ltd. in January 2021. SciSparc Ltd. was incorporated in 2004 and is headquartered in Tel Aviv, Israel.
Home Page: scisparc.com
SPRC Technical Analysis
Tower A
Tel Aviv,
6971916
Israel
Phone:
972 3 715777
Officers
| Name | Title |
|---|---|
| Mr. Oz Adler C.P.A. | CEO & CFO |
| Mr. Itschak Shrem | Pres & Director |
| Dr. Adi Zuloff-Shani Ph.D. | Chief Technologies Officer |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0.4159 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | 2021-08-30 |
| Fiscal Year End: | December |
| Full Time Employees: | 3 |